Giving early-stage pancreatic cancer patients a CD40 immune-stimulating drug helped jumpstart a T cell attack to the notoriously stubborn tumor microenvironment before surgery and other treatments, according to a new study from researchers in the Abramson Cancer Center (ACC) at the University of Pennsylvania.
A massive study unfolding at 20 college campuses aims to determine how well the Moderna coronavirus vaccine prevents vaccinated people from becoming unwitting carriers of the virus.
BOULDER, Colo. – A week before she would have become eligible for a coronavirus vaccine, Madden Brewster agreed to forgo a shot for months to help scientists answer one of the most pressing questions of the pandemic: When can we all stop wearing our masks?
Brewster, a 24-year-old graduate student at the University of Colorado at Boulder, is as impatient as anyone for the pandemic to end, but delaying her shot may be her most powerful way to contribute. She is one of the first volunteers in a massive study unfolding at 20 college campuses. It aims to determine how well the Moderna vaccine prevents vaccinated people from becoming unwitting carriers of the virus.
About
JAMA Network Open: JAMA Network Open is the new online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.
Share
Getty Images
UW Medicine researchers developed a new test, which measures the quantity and quality of inactive HIV viruses in the genes of people living with HIV.
A new test that measures the quantity and quality of inactive HIV viruses in the genes of people living with HIV may eventually give researchers a better idea of what drugs work best at curing the disease.
Currently no cure exists for HIV and AIDS. But antiretroviral therapy drugs, or ARTs, effectively suppress the virus to undetectable levels, but when ART is stopped, HIV reactivates to rekindle active infection.
Published today in Cell Reports Medicine, the study discusses how a new test, developed jointly by scientists at the University of Washington School of Medicine and Fred Hutchinson Cancer Research Center, will give researchers, and eventually doctors, an easier way to gauge how much HIV virus might reside in a patient’s genome.